

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Updated analysis of the Phase III DUO-O trial demonstrated which of the following outcomes with first-line chemotherapy, bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib compared to chemotherapy and bevacizumab followed by maintenance bevacizumab in the intent-to-treat population of patients with nontumor BRCA-mutated advanced ovarian cancer (OC)?**
 - Significant improvement in progression-free survival (PFS) but not overall survival (OS)
 - Significant improvement in PFS and OS
 - No significant improvement in PFS or OS
- Recent findings from the Phase III KEYNOTE-B96 trial evaluating the addition of pembrolizumab to weekly paclitaxel with or without bevacizumab for patients with platinum-resistant advanced OC reported which efficacy finding?**
 - A statistically significant improvement in OS for all-comers
 - A statistically significant improvement in OS for only those patients whose tumors express PD-L1
 - No significant difference in OS
- What was the approximate objective response rate with raludotatug deruxtecan (R-DXd) for platinum-resistant advanced OC across all doses evaluated in the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study?**
 - 25%
 - 50%
 - 85%
- Which of the following treatment-emergent adverse events is most commonly associated with R-DXd?**
 - Pneumonitis
 - Rash
 - Nausea
- AZD5335 is a novel antibody-drug conjugate targeting which protein?**
 - TROP2
 - HER2
 - Folate receptor alpha